Cerenome Inc(CNSY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.41 | Insider Own | 1.3% | Shs Outstand | 7.6M | Perf Week | -6.91% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 45.85% | Insider Trans | - | Shs Float | 7.5M | Perf Month | -10.26% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -1.04 | Inst Own | 16.16% | Short Float | 10% | Perf Quarter | -54.31% |
| Income | -0.03B | P/S | 3.16 | EPS this Y | 34.41% | Inst Trans | 4.42% | Short Ratio | 6.82 | Perf Half Y | -75.96% |
| Sales | 0.00B | P/B | 2.34 | EPS next 5Y | 80.97% | ROA | -214.01% | Short Interest | 0.75M | Perf YTD | -86.34% |
| Book/sh | 0.75 | P/C | 1.55 | EPS past 3/5Y | 70.82% 59.95% | ROE | -614.05% | 52W High | -90.73% ($18.89) | Perf Year | -88.13% |
| Cash/sh | 1.13 | P/FCF | - | Sales past 3/5Y | 185.5% 76.66% | ROIC | -477.54% | 52W Low | 17.85% ($1.49) | Perf 3Y | -93.91% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 91.97% | Gross Margin | 89.58% | Volatility(W/M) | 10.28% 11.88% | Perf 5Y | -99.72% |
| Dividend TTM | - | EV/Sales | 1.13 | Sales Y/Y TTM | -20.95% | Oper. Margin | -628.12% | ATR (14) | 0.19 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1.35 | EPS Q/Q | -701.84% | Profit Margin | -620.7% | RSI (14) | 42.24 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.35 | Sales Q/Q | -70.43% | SMA20 | -0.72% ($1.76) | Beta | 1.49 | Target Price | $37 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/14 | SMA50 | -24.33% ($2.31) | Rel Volume | 0.39 | Prev Close | $1.73 |
| Employees | 28 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -48.86% -63.08% | SMA200 | -64.67% ($4.95) | Avg Volume(3M) | 0.11M | Price | $1.75 |
| IPO | 2003/10/22 | Option/Short | No/Yes | Trades | 219 | Volume | 43,142 | Change | 1.16% |
A US biotech company that focuses on both diagnosing and developing targeted therapies for central nervous system cancers. The business is built around a core strategy of combining a commercial diagnostic test that analyzes cerebrospinal fluid, a radiotherapeutic candidate, and a data analytics partnership to concentrate on the central nervous system oncology field. The company has refreshed its brand identity by adopting a new name and ticker symbol to better reflect its business focus.
Over the past 1 year, on the lower side
91% below its 1-year high.
Traded less than usual. That is 39% of its average volume.
CNSY has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +34.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $316. Peers typically go for $1,138.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.7%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 16.2%.
Tap to view numbers
It ranks #482 of 594 in the industry
Based on market cap of $13M.
FAQ
What kind of company is CNSY?
CNSY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CNSY?
The market cap of CNSY is approximately $13M, ranking 5,356 within its sector.
What is the 52-week high and low for CNSY?
CNSY has recorded a 52-week high of $18.89 and a low of $1.49.
